Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells

Kei Saito, Tohru Fujiwara, Urara Ota, Shunsuke Hatta, Satoshi Ichikawa, Masahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Masahiro Ishizuka, Tohru Tanaka, Hideo Harigae, Kei Saito, Tohru Fujiwara, Urara Ota, Shunsuke Hatta, Satoshi Ichikawa, Masahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Masahiro Ishizuka, Tohru Tanaka, Hideo Harigae

Abstract

5-Aminolevulinic acid (ALA) is a precursor for the biosynthesis of porphyrins and heme. Although the oral administration of ALA has been widely applied in clinical settings, the dynamics of its absorption, metabolism, and excretion within enterocytes remain unknown. In this study, after enterocytic differentiation, Caco-2 cells were incubated with 200 µM ALA and/or 100 µM sodium ferrous citrate (SFC) for up to 72 h. Both ALA and the combination of ALA and SFC promoted the synthesis of heme, without affecting the expression of genes involved in intestinal iron transport, such as DMT1 and FPN. The enhanced heme synthesis in Caco-2 cells was more pronounced under the effect of the combination of ALA and SFC than under the effect of ALA alone, as reflected by the induced expression of heme oxygenase 1 (HO-1), as well as a reduced protein level of the transcriptional corepressor Bach1. Chromatin immunoprecipitation analysis confirmed Bach1 chromatin occupancy at the enhancer regions of HO-1, which were significantly decreased by the addition of ALA and SFC. Finally, Transwell culture of Caco-2 cells suggested that the administered ALA to the intestinal lumen was partially transported into vasolateral space. These findings enhance our understanding of the absorption and metabolism of ALA in enterocytes, which could aid in the development of a treatment strategy for various conditions such as anemia.

Keywords: 5-Aminolevulinic acid; ALA, 5-aminolevulinic acid; ALAS2, 5-aminolevulinic acid synthase 2; Bach1; CSA, congenital sideroblastic anemia; Caco-2 cell; ChIP, chromatin immunoprecipitation; DMT1, divalent metal transporter 1; FPN, ferroportin; HO-1, heme oxygenase 1; Heme oxygenase 1; PP IX, protoporphyrin IX; RT-PCR, reverse transcription polymerase chain reaction; SFC, sodium ferrous citrate.

Figures

Fig. 1
Fig. 1
Differentiation of human intestinal Caco-2 cells. Quantitative RT-PCR analysis of DMT1, FPN, and HO-1 in Caco-2 cells during days 7–21 after seeding. Data are expressed as mean ± standard error (SE). n = 3; *, p

Fig. 2

ALA treatment enhances heme biosynthesis…

Fig. 2

ALA treatment enhances heme biosynthesis and changes intracellular iron status. A: Cellular pellets…

Fig. 2
ALA treatment enhances heme biosynthesis and changes intracellular iron status. A: Cellular pellets (top) and heme levels (bottom) of Caco-2 cells treated with ALA (200 μM) and/or SFC (100 μM) for 72 h. A representative data was shown among 3 independent experiments. B: Western blot analysis of ferritin (left), HO-1 (center), and Bach1 (right). α-tubulin was used as a loading control. C: Quantitative ChIP analysis to detect endogenous Bach1 occupancy at HO-1 enhancers (i.e., the distal E2 and proximal E1 enhancers), based on control and ALA/SFC-treated Caco-2 cells. The RPII215 promoter and the NECDIN promoter were used as negative controls. Data are expressed as mean ± standard error (SE). n = 3; *, p

Fig. 3

ALA did not affect the…

Fig. 3

ALA did not affect the expression of intestinal iron transporters and minimally changed…

Fig. 3
ALA did not affect the expression of intestinal iron transporters and minimally changed ALA transporters. A: Quantitative RT-PCR analysis of DMT1, FPN, HO-1, and ALAS1 in Caco-2 cells treated with ALA (200 μM) and/or SFC (100 μM) for 72 h. Data are expressed as mean ± standard error (SE). n = 3; *, p

Fig. 4

Iron administration did not affect…

Fig. 4

Iron administration did not affect heme, ALA, and porphyrin concentrations in medium. A:…

Fig. 4
Iron administration did not affect heme, ALA, and porphyrin concentrations in medium. A: Chemiluminescent assay to detect heme concentration of medium. HPLC to detect ALA and porphyrin concentrations in medium. N = 3. B: The calculated distribution of ALA in medium after administration. Assuming that the amount of administered ALA is 100%, ALA collection rate is calculated as the percentage of ALA in each compartment 3 days after administration. Total porphyrin equivalent of ALA is the amount of total porphyrin converted to ALA.
Similar articles
References
    1. Furuyama K., Kaneko K., Vargas P.D. Heme as a magnificent molecule with multiple missions: heme determines its own fate and governs cellular homeostasis. Tohoku J. Exp. Med. 2007;213:1–16. - PubMed
    1. Kennedy J.C., Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol. B. 1992;14:275–292. - PubMed
    1. Fujiwara T., Okamoto K., Niikuni R., Takahashi K., Okitsu Y., Fukuhara N., Onishi Y., Ishizawa K., Ichinohasama R., Nakamura Y., Nakajima M., Tanaka T., Harigae H. Effect of 5-aminolevulinic acid on erythropoiesis: a preclinical in vitro characterization for the treatment of congenital sideroblastic anemia. Biochem. Biophys. Res. Commun. 2014;454:102–108. - PubMed
    1. Rodriguez B.L., Curb J.D., Davis J., Shintani T., Perez M.H., Apau-Ludlum N., Johnson C., Harrigan R.C. Use of the dietary supplement 5-aminiolevulinic acid (5-ALA) and its relationship with glucose levels and hemoglobin A1C among individuals with prediabetes. Clin. Transl. Sci. 2012;5:314–320. - PMC - PubMed
    1. Higashikawa F., Noda M., Awaya T., Tanaka T., Sugiyama M. 5-aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects. Nutrition. 2013;29:1030–1036. - PubMed
Show all 31 references
Related information
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Fig. 2
Fig. 2
ALA treatment enhances heme biosynthesis and changes intracellular iron status. A: Cellular pellets (top) and heme levels (bottom) of Caco-2 cells treated with ALA (200 μM) and/or SFC (100 μM) for 72 h. A representative data was shown among 3 independent experiments. B: Western blot analysis of ferritin (left), HO-1 (center), and Bach1 (right). α-tubulin was used as a loading control. C: Quantitative ChIP analysis to detect endogenous Bach1 occupancy at HO-1 enhancers (i.e., the distal E2 and proximal E1 enhancers), based on control and ALA/SFC-treated Caco-2 cells. The RPII215 promoter and the NECDIN promoter were used as negative controls. Data are expressed as mean ± standard error (SE). n = 3; *, p

Fig. 3

ALA did not affect the…

Fig. 3

ALA did not affect the expression of intestinal iron transporters and minimally changed…

Fig. 3
ALA did not affect the expression of intestinal iron transporters and minimally changed ALA transporters. A: Quantitative RT-PCR analysis of DMT1, FPN, HO-1, and ALAS1 in Caco-2 cells treated with ALA (200 μM) and/or SFC (100 μM) for 72 h. Data are expressed as mean ± standard error (SE). n = 3; *, p

Fig. 4

Iron administration did not affect…

Fig. 4

Iron administration did not affect heme, ALA, and porphyrin concentrations in medium. A:…

Fig. 4
Iron administration did not affect heme, ALA, and porphyrin concentrations in medium. A: Chemiluminescent assay to detect heme concentration of medium. HPLC to detect ALA and porphyrin concentrations in medium. N = 3. B: The calculated distribution of ALA in medium after administration. Assuming that the amount of administered ALA is 100%, ALA collection rate is calculated as the percentage of ALA in each compartment 3 days after administration. Total porphyrin equivalent of ALA is the amount of total porphyrin converted to ALA.
Similar articles
References
    1. Furuyama K., Kaneko K., Vargas P.D. Heme as a magnificent molecule with multiple missions: heme determines its own fate and governs cellular homeostasis. Tohoku J. Exp. Med. 2007;213:1–16. - PubMed
    1. Kennedy J.C., Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol. B. 1992;14:275–292. - PubMed
    1. Fujiwara T., Okamoto K., Niikuni R., Takahashi K., Okitsu Y., Fukuhara N., Onishi Y., Ishizawa K., Ichinohasama R., Nakamura Y., Nakajima M., Tanaka T., Harigae H. Effect of 5-aminolevulinic acid on erythropoiesis: a preclinical in vitro characterization for the treatment of congenital sideroblastic anemia. Biochem. Biophys. Res. Commun. 2014;454:102–108. - PubMed
    1. Rodriguez B.L., Curb J.D., Davis J., Shintani T., Perez M.H., Apau-Ludlum N., Johnson C., Harrigan R.C. Use of the dietary supplement 5-aminiolevulinic acid (5-ALA) and its relationship with glucose levels and hemoglobin A1C among individuals with prediabetes. Clin. Transl. Sci. 2012;5:314–320. - PMC - PubMed
    1. Higashikawa F., Noda M., Awaya T., Tanaka T., Sugiyama M. 5-aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects. Nutrition. 2013;29:1030–1036. - PubMed
Show all 31 references
Related information
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Fig. 3
Fig. 3
ALA did not affect the expression of intestinal iron transporters and minimally changed ALA transporters. A: Quantitative RT-PCR analysis of DMT1, FPN, HO-1, and ALAS1 in Caco-2 cells treated with ALA (200 μM) and/or SFC (100 μM) for 72 h. Data are expressed as mean ± standard error (SE). n = 3; *, p

Fig. 4

Iron administration did not affect…

Fig. 4

Iron administration did not affect heme, ALA, and porphyrin concentrations in medium. A:…

Fig. 4
Iron administration did not affect heme, ALA, and porphyrin concentrations in medium. A: Chemiluminescent assay to detect heme concentration of medium. HPLC to detect ALA and porphyrin concentrations in medium. N = 3. B: The calculated distribution of ALA in medium after administration. Assuming that the amount of administered ALA is 100%, ALA collection rate is calculated as the percentage of ALA in each compartment 3 days after administration. Total porphyrin equivalent of ALA is the amount of total porphyrin converted to ALA.
Fig. 4
Fig. 4
Iron administration did not affect heme, ALA, and porphyrin concentrations in medium. A: Chemiluminescent assay to detect heme concentration of medium. HPLC to detect ALA and porphyrin concentrations in medium. N = 3. B: The calculated distribution of ALA in medium after administration. Assuming that the amount of administered ALA is 100%, ALA collection rate is calculated as the percentage of ALA in each compartment 3 days after administration. Total porphyrin equivalent of ALA is the amount of total porphyrin converted to ALA.

References

    1. Furuyama K., Kaneko K., Vargas P.D. Heme as a magnificent molecule with multiple missions: heme determines its own fate and governs cellular homeostasis. Tohoku J. Exp. Med. 2007;213:1–16.
    1. Kennedy J.C., Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol. B. 1992;14:275–292.
    1. Fujiwara T., Okamoto K., Niikuni R., Takahashi K., Okitsu Y., Fukuhara N., Onishi Y., Ishizawa K., Ichinohasama R., Nakamura Y., Nakajima M., Tanaka T., Harigae H. Effect of 5-aminolevulinic acid on erythropoiesis: a preclinical in vitro characterization for the treatment of congenital sideroblastic anemia. Biochem. Biophys. Res. Commun. 2014;454:102–108.
    1. Rodriguez B.L., Curb J.D., Davis J., Shintani T., Perez M.H., Apau-Ludlum N., Johnson C., Harrigan R.C. Use of the dietary supplement 5-aminiolevulinic acid (5-ALA) and its relationship with glucose levels and hemoglobin A1C among individuals with prediabetes. Clin. Transl. Sci. 2012;5:314–320.
    1. Higashikawa F., Noda M., Awaya T., Tanaka T., Sugiyama M. 5-aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects. Nutrition. 2013;29:1030–1036.
    1. van den Boogert J., van Hillegersberg R., de Rooij F.W., de Bruin R.W., Edixhoven-Bosdijk A., Houtsmuller A.B., Siersema P.D., Wilson J.H., Tilanus H.W. 5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration. J. Photochem. Photobiol. B. 1998;44:29–38.
    1. Dalton J.T., Meyer M.C., Golub A.L. Pharmacokinetics of aminolevulinic acid after oral and intravenous administration in dogs. Drug. Metab. Dispos. 1999;27:432–435.
    1. Dalton J.T., Yates C.R., Yin D., Straughn A., Marcus S.L., Golub A.L., Meyer M.C. Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. J. Pharm. Exp. Ther. 2002;301:507–512.
    1. Loh C.S., MacRobert A.J., Bedwell J., Regula J., Krasner N., Bown S.G. Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. Br. J. Cancer. 1993;68:41–51.
    1. Regula J., MacRobert A.J., Gorchein A., Buonaccorsi G.A., Thorpe S.M., Spencer G.M., Hatfield A.R., Bown S.G. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study. Gut. 1995;36:67–75.
    1. Sassa S. Sequential induction of heme pathway enzymes during erythroid differentiation of mouse Friend leukemia virus-infected cells. J. Exp. Med. 1976;143:305–315.
    1. Takahashi S., Masuda T. High throughput heme assay by detection of chemiluminescence of reconstituted horseradish peroxidase. Comb. Chem. High Throughput Screen. 2009;12:532–535.
    1. Miyajima K., Hirata M., Yoshida T., Kosaka H., Okayama A. Study on measurement of delta-aminolevulinic acid in plasma by high-performance liquid chromatography. J. Chromatogr. B. 1994;654:165–169.
    1. Kondo M. Porphyrins in urine, blood, and feces and delta-aminolevulinic acid and porphobilinogen. Nihon Rinsho. 1995;53:1364–1370.
    1. Bermudez Moretti M., Correa Garcia S., Perotti C., Batlle A., Casas A. Delta-Aminolevulinic acid transport in murine mammary adenocarcinoma cells is mediated by beta transporters. Br. J. Cancer. 2002;87:471–474.
    1. Fujiwara T., Saitoh H., Inoue A., Kobayashi M., Okitsu Y., Katsuoka Y., Fukuhara N., Onishi Y., Ishizawa K., Ichinohasama R., Harigae H. 3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation. J. Biol. Chem. 2014;289:8121–8134.
    1. Fujiwara T., O'Geen H., Keles S., Blahnik K., Linnemann A.K., Kang Y.A., Choi K., Farnham P.J., Bresnick E.H. Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. Mol. Cell. 2009;36:667–681.
    1. Canonne-Hergaux F., Gruenheid S., Ponka P., Gros P. Cellular and subcellular localization of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron. Blood. 1999;93:4406–4417.
    1. Donovan A., Brownlie A., Zhou Y., Shepard J., Pratt S.J., Moynihan J., Paw B.H., Drejer A., Barut B., Zapata A., Law T.C., Brugnara C., Lux S.E., Pinkus G.S., Pinkus J.L., Kingsley P.D., Palis J., Fleming M.D., Andrews N.C., Zon L.I. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000;403:776–781.
    1. Eady J.J., Wormstone Y.M., Heaton S.J., Hilhorst B., Elliott R.M. Differential effects of basolateral and apical iron supply on iron transport in Caco-2 cells. Genes Nutr. 2015;10:1–15.
    1. Uc A., Britigan B.E. Does heme oxygenase-1 have a role in Caco-2 cell cycle progression? Exp. Biol. Med. (Maywood) 2003;228:590–595.
    1. Sassa S. Modern diagnosis and management of the porphyrias. Br. J. Haematol. 2006;135:281–292.
    1. Igarashi K., Watanabe-Matsui M. Wearing red for signaling: the heme-bach axis in heme metabolism, oxidative stress response and iron immunology. Tohoku J. Exp. Med. 2014;232:229–253.
    1. Fiorito V., Forni M., Silengo L., Altruda F., Tolosano E. Crucial role of FLVCR1a in the maintenance of intestinal heme homeostasis. Antioxid. Redox Signal. 2015;23:1410–1423.
    1. Ajioka R.S., Phillips J.D., Kushner J.P. Biosynthesis of heme in mammals. Biochim. Biophys. Acta. 1763;2006:723–736.
    1. Nishio Y., Fujino M., Zhao M., Ishii T., Ishizuka M., Ito H., Takahashi K., Abe F., Nakajima M., Tanaka T., Taketani S., Nagahara Y., Li X.K. 5-Aminolevulinic acid combined with ferrous iron enhances the expression of heme oxygenase-1. Int. Immunopharmacol. 2014;19:300–307.
    1. Hagiya Y., Adachi T., Ogura S., An R., Tamura A., Nakagawa H., Okura I., Mochizuki T., Ishikawa T. Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy. J. Exp. Ther. Oncol. 2008;7:153–167.
    1. Hou J., Cai S., Kitajima Y., Fujino M., Ito H., Takahashi K., Abe F., Tanaka T., Ding Q., Li X.K. 5-Aminolevulinic acid combined with ferrous iron induces carbon monoxide generation in mouse kidneys and protects from renal ischemia-reperfusion injury. Am. J. Physiol. Ren. Physiol. 2013;305:F1149–F1157.
    1. Frolund S., Marquez O.C., Larsen M., Brodin B., Nielsen C.U. Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1) Br. J. Pharmacol. 2010;159:1339–1353.
    1. Xie Y., Hu Y., Smith D.E. The proton-coupled oligopeptide transporter 1 plays a major role in the intestinal permeability and absorption of 5-aminolevulinic acid. Br. J. Pharmacol. 2016;173:167–176.
    1. Zong W.X., Rabinowitz J.D., White E. Mitochondria and cancer. Mol. Cell. 2016;61:667–676.

Source: PubMed

3
Předplatit